Objective: To observe and explore the clinical efficacy of Flupentixol and Melitracen combined with Mosapride and Pinaverium Bromide in treating functional dyspepsia (FD) in perimenopausal women. Methods: Sixty perimenopausal female patients with FD admitted to our hospital from February 2023 to March 2025 were selected. Using simple random grouping, patients were divided into a conventional group (treated with Mosapride and Pinaverium Bromide, n=30) and a treatment group (receiving Mosapride, Pinaverium Bromide, plus Flupentixol and Melitracen, n=30). The treatment course for both groups was 4 weeks. The two groups were compared in terms of therapeutic effects, the time taken for symptom improvement, gastrointestinal hormones [Motilin (MTL), Gastrin (GAS), Somatostatin (SS)], and adverse events. Results: Post-treatment, the overall efficacy rate of the treatment group outperformed that of the conventional group (P<0.05) . The treatment group also had a shorter duration for the improvement of belching, epigastric pain, and postprandial fullness symptoms in comparison with the conventional group (P<0.05) . Serum MTL levels increased, while GAS and SS levels decreased in both groups; furthermore, the MTL level in the treatment group was higher than that in the conventional group, and the GAS and SS levels were lower than those in the conventional group (P<0.05) . In the treatment phase, the incidence of adverse events like dizziness, gastric discomfort, tremor, and palpitations did not differ significantly between the two groups (P>0.05). Conclusion: The combination of Flupentixol and Melitracen with Mosapride and Pinaverium Bromide can effectively alleviate the clinical symptoms of functional dyspepsia in perimenopausal women, regulate gastrointestinal hormones, with significant clinical effects and good safety.